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Diseases affecting motor neurons, such as amyotrophic lateral sclerosis (Lou Gerhig's disease), hereditary spastic paraplegia and spinal bulbar
muscular atrophy (Kennedy's disease) are a heterogeneous group of chronic progressive diseases and are among the most puzzling yet untreatable
illnesses. Over the last decade, identification of mutations in genes predisposing to these disorders has provided the means to better understand
their pathogenesis. The discovery 13 years ago of SOD1 mutations linked to ALS, which account for less than 2% of total cases, had a major
impact in the field. However, despite intensive research effort, the pathways leading to the specific motor neurons degeneration in the presence of
SOD1 mutations have not been fully identified. This review provides an overview of the genetics of both familial and sporadic forms of ALS.
© 2006 Elsevier B.V. All rights reserved.Keywords: Amyotrophic lateral sclerosis; Genetic; FALS; SALS1. Introduction
Amyotrophic lateral sclerosis (ALS) is the most common
adult onset neurodegenerative disorder characterized by the
death of large motor neurons in the cerebral cortex and spinal
cord [1]. Dysfunction and death of these cell populations lead to
progressive muscle weakness, atrophy and, ultimately, paralysis
and death within 3 to 5 years after disease onset [2]. The disease
occurs in sporadic and familial forms, with an estimated
incidence of between 0.4 and 1.8 per 100,000, which is quite
uniform throughout the world, with the exception of several
high incidence foci on the Pacific island of Guam and on the Kii
peninsula of Japan. Thus, the life-long risk to develop ALS,
considering a 70-year-old life expectancy, is approximately 1 in
2000. Though most cases of ALS are sporadic, 10% of cases
have affected relatives, some with clear Mendelian inheritance
and high penetrance [2]. Inheritance in familial ALS (FALS) is
usually autosomal dominant, but some autosomal recessive
pedigrees have been described [3–8]. To date, mutations in only
one gene, called Cu/Zn superoxide dismutase (SOD1), lead to
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doi:10.1016/j.bbadis.2006.01.00415% of FALS cases [9]. Cognitive impairment and dementia
also coexist with ALS in approximately 3–5% of the cases [10].
The mechanism whereby mutant SOD1 causes specific
degeneration of motor neurons remains unclear. The identifi-
cation of other genes responsible for the disease and the
understanding of the molecular pathways involved will bring
some new insights into the mechanisms of disease pathogenesis,
and will elucidate the underlying mechanism for specific motor
neuron degeneration observed in ALS. The focus of this review
is on the genetic epidemiology of ALS with a brief discussion
on common molecular pathways underlying different motor
neuron disorders.
2. Familial ALS
To date, eight FALS loci and six ALS related genes have
been identified by genetic analysis, through linkage studies and
positional cloning (Table 1). Both autosomal dominant and
autosomal recessive forms occur. Unfortunately, only one of
these genes, named SOD1, leads to a classical adult onset form
of ALS. Despite intensive research efforts, the mapping and the
identification of genes responsible for classical form of FALS
has met with limited success. This difficulty arises in part
because large families with sufficient statistical power for
Table 1
Reported FALS/MND loci
FALS/MND loci
(OMIM)
Gene
(OMIM)
Chromosomal
location
References
Adult onset dominant typical ALS
ALS1a (105400) SOD1
(147450)
21q22,1 [11,12]
ALS3 (606640) 18q21 [54]
ALS6 (608030) 16q12 [61–63]
ALS7 (608631) 20ptel-p13 [63]
Adult onset dominant atypical ALS
ALS with frontotemporal
dementia (105550)
9q21–q22 [73]
ALS with dementia/
parkinsonism
(600274)
MAPT
(157140)
17q21.1 [77]
Progressive LMN
disease (607641)
DCTN1
(601143)
2p13 [88]
ALS8 (608627) VAPB
(605704)
20q13.3 [64,65]
Juvenile onset dominant ALS
ALS4 (602433) SETX
(608465)
9q34 [55,57]
Juvenile onset recessive ALS
ALS2 (205100) ALS2
(606352)
2q33 [6,8,40]
ALS5 (602099) 15q15.1–q21.1 [7]
ALS: amyotrophic lateral sclerosis. LMN: lower motor neuron. MND: motor
neuron disease.
a Note that both dominant and recessive linked-SOD1 mutations have
been reported.
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age-dependant penetrance of the disease, and the relative short
survival time of affected ALS patients. While the study of
SOD1 has led to great advances in understanding the molecular
mechanisms and underlying pathogenesis of this disease,
identifying mutations in other genes in ALS patients will be
of significant impact in the field. Because familial and sporadic
forms of ALS are clinically and pathologically similar,
understanding the familial form will illuminate possible
epidemiological and pathophysiological mechanisms in spo-
radic ALS.
2.1. ALS1 (OMIM: 105400)
The mapping of ALS1 was first reported in 1991 with
linkage to chromosome 21 [11]. In 1993, eleven different
missense mutations in the SOD1 gene were identified,
confirming it as the causative gene [12]. The SOD1 gene is
located on chromosome 21q22.1, spans about 9.3-kilobases
(kb) of genomic DNA, comprises five exons and encodes for a
153-amino acid long protein of 16 kiloDalton (kDa). Mutations
in the SOD1 gene, now identified in all exons of the gene, are
responsible for approximately 15 to 20% of FALS, representing
only 1–2% of all patients with ALS [9,12]. The clinical features
of SOD1-linked ALS appear to be indistinguishable from ALSwithout SOD1mutations, although in the former the disease has
a slight tendency to begin in the limbs rather than the bulbar
region [13]. SOD1 had been intensively investigated prior to its
association with FALS due to its biological importance as an
antioxidant. It is highly conserved through evolution and is
expressed in all cells in eukaryotes. SOD1 is an abundant
protein constituting approximately 1% of total cytosolic protein.
Three different superoxide dismutases are encoded in the
human genome: Cu/Zn SOD (SOD1), Mn SOD (SOD2) and
extracellular SOD (SOD3). Together, they are one of the several
types of enzymes in a biochemical pathway that scavenges free
radical oxygen (O2
–) produced by mitochondrial respiration and
other biological processes. All these metalloenzymes contain a
redox-sensitive transition metal within their active site. They
dismutate superoxide to hydrogen peroxide (H2O2), which is
then converted to water by either catalase or glutathione
peroxydase. In the presence of iron, hydrogen peroxide can
generate hydroxyl radical (SOH), a particularly devastating free
radical species.
2.1.1. Brief overview of SOD1 mutations
Different SOD1 mutations cause distinct phenotypes that
differ with respect to penetrance, age of onset, disease
progression, survival and clinical manifestations. All SOD1
mutations are dominant, except for the substitution of alanine
for aspartate at position 90 (D90A), which can be either
recessive or dominant [14]. An ALS family with affected
individuals carrying a single copy of the SOD1 D90A recessive
mutation and also a copy of a novel, D96N mutation have been
also reported [15]. This is the first description of compound
heterozygosity in ALS, and also suggests that D96N may be
another recessive mutation. To date, over one hundred and
twenty-two different SOD1 mutations have been reported,
including one hundred and fifteen amino acid substitutions,
three insertions and four deletions (http://www.alsod.org). Most
of the individual mutations result in substitution of one single
amino acid. Such substitutions have been identified in seventy-
four different codons and represent almost half of the one
hundred and fifty-three amino acid residues of the wild-type
Cu/Zn SOD protein.
An epidemiological study of the SOD1 mutations in FALS
established a number of interesting facts [16]: (1) mutations in
SOD1 are highly specific to FALS as such mutations were not
detected in over two hundred normal individuals, nor in nearly
one hundred patients with Parkinsonism or in patients with
other neurological disorders; (2) mutations are detected in only
23% of ALS families, suggesting that additional gene defects
may be responsible for ALS; (3) the A4V mutation is the most
commonly detected of all SOD1 mutations in familial ALS, and
give raise to the most aggressive form of ALS, with reduced
survival time after onset (i.e., 1.2 years as compared to 2.5 years
for all other familial ALS patients) [17]. In contrast, the H46R
mutation located within the copper binding domain leads to an
average life expectancy of 18 years after disease onset [18,19].
It is also interesting to note that the reported H48Q mutation,
which is adjacent to the H46R mutation, leads to a severe form
of ALS with rapid progression [20]. There are also considerable
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families, including age of onset and rate of disease progression.
Usually, the mean age of onset is slightly earlier in SOD1-linked
FALS (46.9 years) compared to non-SOD1 patients (50.5
years), and the mean age of onset can also vary among different
SOD1 mutations [16]. It is interesting to note that SOD1
mutations that are associated with earlier age of onset, such as
G37R and L38V, are different from those associated with a more
severe phenotype, such as A4V, suggesting that SOD1 enzyme
properties that modulate the timing of disease onset differ from
those involved in the rate of disease progression [16]. Therefore,
it is apparent that the clinical phenotype must be modified by
other genetic and/or environmental factors. Keeping this in
mind, haplotype analysis has demonstrated that SOD1 D90A
linked-FALS arose from a single founder and interestingly, a
cis-acting element falling within the regulatory region of
SOD1 and modifying the recessive haplotype has been
suggested [21]. Recently, another study of A4V mutation
carriers identified a small common haplotype surrounding the
SOD1 locus, suggesting again a founder effect, which may
partly explain the high prevalence of this mutation in North
America [22]. This finding also leads to the hypothesis that a
genetic variant within the haplotypic region might be respon-
sible for the accelerated course of the disease progression seen
in A4V cases. Unfortunately, DNA sequencing of four candi-
date genes within the reported region failed to identify any
genetic modifiers [23].
2.1.2. Mutant SOD1 animal models
Overexpression of either G37R, G85R, G86R, G93A, H46R/
H48Q or H46R/H48Q/H63G/H120G mutant SOD1 protein in
mice leads to a neurodegenerative disease that is quite similar to
the human illness [24–29]. Transgenic rats overexpressing
G93A or H46R mutant SOD1, also develop an ALS-like pheno-
type [30,31]. Each model of ALS is phenotypically consistent
with a given specific mutation, and they vary in their age at
onset, disease progression, and particular histopathological fea-
tures, mimicking the diversity of phenotypes observed in human
ALS. Furthermore, the variable penetrance and age at onset
caused by SOD1 mutations can be also be mimicked in trans-
genic mouse models of ALS by varying the mouse strain on
which a mutation is carried [32]. This background strain effect
suggests an existence of strong modifying genetic factors in
ALS.
The initial description of SOD1 gene mutations in familial
ALS led to the hypothesis that the disease was caused by altered
free radical scavenging, resulting from compromised enzymatic
activity due to the loss of Cu/Zn function [17]. This loss of
function hypothesis was further disproved as SOD1 knock out
mice, in which the murine Sod1 gene was disrupted, do not have
motor neuron disease [33]. Moreover, as mentioned, over-
expression of mutant SOD1 protein leads to an ALS-like
phenotype in mice. A toxic gain of function rather than a loss of
function of mutant SOD1 gene is also indicated by the finding
that wild-type human SOD1 gene, expressed at similar protein
levels, does not cause disease, and indeed is neuroprotective in a
variety of assays of oxidative stress [34]. Proposed pathogeneticmechanisms include oxidative stress, glutamate excitotoxicity,
neurofilament disorganization, copper toxicity and apoptotic
cell death [35]. However, the mechanism through which mutant
SOD1 exerts toxicity and results in selective motor neuron
death remains uncertain.
The use of mouse models has been of particular importance in
studying the pathogenesis of amyotrophic lateral sclerosis. All
publishedmousemodels have used the endogenousmurine Sod1
promoter that results in high levels of expression of the mutant
transgene in all tissues. Although these models implicate mutant
SOD1 in the development of motor neuron degeneration, many
questions regarding the mechanism of pathogenesis remain
unanswered. One of the central mysteries inALS research is why
a ubiquitously expressed gene such as SOD1 causes selective
devastation to motor neurons in the absence of pathology in
other tissues. In an attempt to address this issue, a study
conducted in our lab showed that neuron-specific expression
does not cause motor neuron cell death, in contrast to
observations in transgenic lines overexpressing FALS-associat-
ed SOD1 mutations in a constitutive manner [36]. One possible
explanation is that expression of the mutant protein in motor
neurons may not be sufficient to lead to the development of a
neurodegenerative disease in mice, suggesting that mutant
SOD1 expression in other cells may be necessary for the
development of the disease. This finding was later confirmed by
other groups, where specific expression of mutant SOD1 in
either neurons [37] or in astrocytes [38] does not lead to motor
neuron degeneration in mice. Furthermore, study of chimeric
mice, created from mixtures of normal and mutant SOD1-
expressing cells, showed that motor neuron toxicity requires
damage from mutant SOD1 acting within non-neuronal cells,
and that motor neurons expressing only wild-type SOD1
develop some aspects of ALS pathology [39]. Most impor-
tantly, they have shown that motor neurons containing mutant
SOD1 survived longer when surrounded by cells expressing
wildtype SOD1, further suggesting that toxicity of SOD1
mutations is not cell autonomous. This alteration of mutant
cells by surrounding wildtype cells bodes well for the future of
stem cell therapy. Thus, the ALS-like pathology seen in the
chimeras but not in the mice with mutant SOD1 overexpression
in neurons or astrocytes alone suggests that expression of
mutant SOD1 in both cell types is necessary to initiate the
disease process.
2.2. ALS2 (OMIM: 205100)
The initial description of the rare juvenile-onset recessive
ALS2 locus on chromosome 2 was published in 1994 [40]. A
positional cloning approach, primarily in families of Arabic
origin with a rare juvenile-onset recessive form of the disease,
led to the identification of the ALS2 gene 7 years later [6,8].
These families displayed a juvenile onset (age 3 to 23 years) of
progressive spasticity of the limbs, facial and pharyngeal
muscles. The mutation detected in this family was a single base-
pair deletion in a novel gene, predicted to result in a frameshift
mutation leading to a premature stop codon and truncated
protein. Mutations in ALS2 account for different but relatively
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there are ten reported mutations in the ALS2 gene leading to
either ALS, where both upper/lower motor neurons are
affected, or to primary lateral sclerosis (PLS), or infantile
onset ascending hereditary spastic paraplegia (IAHSP) where
only upper motor neurons are affected [3–6,8]. The ALS2 gene
encodes for alsin, a protein with multiple motifs homologous to
guanine–nucleotide exchange factors. The protein contains
similarity to three domains: an amino-terminal region that
shares homology to RCC1 (regulator of chromatin conden-
sation), a Pleckstrin-DB1 centrally located domain and a
carboxyl-terminal VPS9 domain. These domains harbor char-
acteristics of various guanine exchange factors (GEFs). The
protein also contains a motif called MORN (Membrane
Occupation and Recognition Nexus) located between the
Pleckstrin and VPS9 domains. MORN motifs are not fully
characterized and they are found in a number of proteins of
unknown function. Alsin has been shown to function as a GEF
for Ran, Rho and Rab GTPases [41]. It has also been shown
that alsin binds specifically to small GTPase Rab5 and func-
tions as a GEF for Rab5 through the VPS9 domain, suggesting
that alsin may be involved in the organization of the actin
cytoskeleton and vesicle trafficking [42,43]. In addition, alsin
can also interact specifically with Rac1, a small Rho GTPase
[44,45]. Interestingly, alsin can also binds specifically to
different mutant variants of the SOD1 protein through its
RhoGEF–Pleckstrin domain [46]. Further investigation of this
physical interaction between alsin and SOD1 may help
understand the pathogenesis underlying ALS and other motor
neuron diseases.
ALS2 comprises thirty-three exons spanning 80 kb of
genomic human DNA. This gene is predicted to encode a 184-Table 2
Reported ALS2 mutations
Variants a Previous name Exon Nb Alsin isoforms Disease (O
138delA 261delAT Exon 3 Short/Long Juvenile
ALS (2051
553delA 553delA Exon 4 Short/Long Juvenile
ALS (2051
1007–1008delTA 1130delAT Exon 4 Short/Long IAHSP (60
1425–1426delAG 1425delAG Exon 5 Long Juvenile
PLS (60635
1470 GNT 1470 GNT Exon 6 Long IAHSP (60
1867–1868delCT 1867delCT Exon 9 Long Juvenile
PLS (60635
2537–2538delAT 2660delAT Exon 13 Long IAHSP (60
2292 CNT 3115 CNT Exon 18 Long IAHSP (60
3619delA 3742delA Exon 23 Long IAHSP (60
4721delT 4844delT Exon 32 Long IAHSP (60
ALS: amyotrophic lateral sclerosis. PLS: primary lateral sclerosis. IAHSP: infantile
a Variant were renamed according to the published guidelines (Antonarakis SE, 1
NM_020919.2 and nucleotide “A” from the ATG initiation codon is referred as 1.kDa protein consisting of 1657 amino acids. ALS2 mRNA can
be alternatively spliced to produce alsin and another shorter
transcript of about 2.6 kb (396 amino acid long) [6,8]. This
short variant is produced by alternate splicing at the 5′ donor
site after exon 4, resulting in a premature termination of the
transcript after twenty-five amino acid residues in intron 4.
However, the existence of an endogenous functional short
form of alsin has been questioned [47].
2.2.1. ALS2 reported mutations
Eight out of ten reported mutations in the ALS2 gene are
deleterious mutation (Table 2) [4–6,8,48]. One nonsense
mutation and one splice site mutation have also been reported
[3,4]. All reported mutations lead to premature termination of
the transcript and a truncated protein. All affected patients are
homozygous and all parents and unaffected sibs are heterozy-
gous for one of these reported mutations. The pattern of
inheritance and the nature of the mutations identified in this
gene suggest that motor neuron degeneration seen in ALS2
patients results from a loss of function. A common feature of all
reported mutations is the loss of the carboxy-terminal VPS9
domain, suggesting that loss of VPS9-associated GEF function
results in a deficit in intracellular cell trafficking. Many other
variations have been found in ALS2, but each variant identified
was also present in control subjects, suggesting that mutations
in ALS2 are not a common cause of FALS and SALS [49–51].
As mentioned, mutations in this gene could also cause other
motor neuron diseases such as ALS, PLS and IAHSP. It was
first hypothesized that mutations affecting both transcripts
could lead to ALS, the most severe form of the disease, while
mutations affecting only the long isoform could cause milder
phenotypes, such as PLS and IAHSP. However, this theory wasMIM) Origin Variant type Effect Ref.
00)
Tunesian 1-bp deletion at codon 46 Premature stop
at codon 50
[6,8]
00)
Turkish 1-bp deletion at codon 553 Premature stop
at codon 189
[48]
7225) Italian 2-bp deletion at codon 336 Premature stop
at codon 341
[4]
3)
Kuwaiti 2-bp deletion at codon 475 Premature stop
at codon 497
[6]
7225) French CAG-acceptor splice
site mutation
10-bp deletion
in the transcript
[4]
3)
Saudi 2-bp deletion at codon 623 Premature stop
at codon 646
[8]
7225) Italian 2-bp deletion at codon 846 Premature stop
at codon 853
[4]
7225) Buchari
Jewish
Nonsense C to T mutation Premature stop
at codon 998
[3]
7225) Algerian 1-bp deletion at codon 1207 Premature stop
at codon 1208
[4]
7225) Pakistani 1-bp deletion at codon 1574 Premature stop
at codon 1618
[5]
ascending hereditary spastic paraplegia.
998). The numbers refer to the position in the ALS2 messenger RNA sequence
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found among all reported mutations.
2.2.2. Alsin knockout mouse
Two different groups have reported the generation of an alsin
knockout mouse [52,53]. However, no major motor deficits
consistent with ALS or other motor neuron diseases were present
in these models. Even though ALS2 knockout mice lack obvious
developmental abnormalities, primary cultured neurons derived
from these mice are more susceptible to oxidative stress when
compared with wild-type controls [52]. These findings suggest
that loss of ALS2 function is insufficient to cause major motor
deficits in mouse, but predisposes neurons to oxidative stress.
2.3. ALS3 (OMIM: 606640)
A genome-wide screen of a large pedigree with autosomal
dominant adult-onset ALS yielded evidence for linkage to
chromosome 18q21 with a maximum lod score of 4.5 [54]. This
large European family with at least twenty affected members
has no mutations in the SOD1 gene. This suggests that the
ALS3 locus is thus a genetically distinct form of FALS and it is
the first reported adult-onset dominant ALS locus since ALS1.
Clinical presentation of affected family members is pretty
uniform with typical ALS features with upper and lower motor
neuron signs and with progressive weakness involving all four
limbs. The mean age at onset is 45 years and the mean duration
of the disease is 5 years.
The reported 7.5-centiMorgan (cM), 8-Megabase (Mb)
region is flanked by markers D18S846 and D18S1109. The
candidate region contains around 30 genes including two very
promising candidate genes in terms of biological function.
Unfortunately, direct sequencing of these two candidate genes
(TXNL and FECH) did not reveal any causing mutation (data
not published).
2.4. ALS4 (OMIM: 602433)
A study of an 11-generation pedigree with a chronic and
slowly progressive rare autosomal dominant form of juvenile
ALS established linkage to chromosome 9q34 with a maximum
lod score of 18.8 [55]. The region lies between markers
D9S1831 and D9S164 and defines an interval of 5-cM. The
strong genetic evidence combined with the absence of SOD1
mutations suggested that this locus is genetically distinct from
previously mapped familial ALS syndromes. Further analysis
on this pedigree refined the position of the ALS4 locus to a 0.5-
Mb interval [56]. More recently, different missense mutations in
the senataxin gene (SETX) were found in three unrelated
families from the United States, Belgium and Austria with a
subtype of dominant ALS [57]. The SETX gene comprises
twenty-six exons spanning over 91-kb of genomic DNA. The
predicted 302.8-kDa protein is 2,677-amino acids long and
contains a C-terminal classical 7-motif domain found in the
superfamily 1 of DNA/RNA helicases. This gene also shares
strong homology to human RENT1 and IGHMBP2, two genes
known to have roles in RNA processing. Interestingly,mutations in IGHMBP2 are linked to spinal muscular atrophy,
a motor neuron disease characterized by the degeneration of
lower motor neurons [58].
2.4.1. SETX mutations
Different SETX mutations causing distinct phenotypes have
been reported. It appears that heterozygous dominant mutations
within SETX lead to the described form of ALS4, and loss of
function recessive mutations cause an unrelated disorder called
ataxia-oculomotor apraxia type 2 (AOA2: OMIM 606002).
Ataxia-oculomotor apraxia (AOA) is a genetically heteroge-
neous group of autosomal recessive disorders characterized by
cerebellar ataxia/atrophy, oculomotor apraxia, late peripheral
neuropathy, immunodeficiency and slow progression leading to
severe motor handicap. Three distinct heterozygous missense
mutations in this gene, L389S, R2136H and T3I, have been
linked to ALS [57], while homozygous deletions including
missense, nonsense and deleterious mutations have been
associated with AOA2 [59,60]. SETX mutations lead to two
phenotypically different disorders which have distinct patterns
of inheritance, suggesting that ALS4 is likely to be caused by a
gain of function mechanism of the mutated senataxin protein.
2.5. ALS5 (OMIM: 602099)
ALS5-linked families show typical ALS features and appear
to be present in both North African and European populations.
The onset of the disease is juvenile, ranging from 8 to 18 years,
with slow progression [7]. In contrast with ALS2 patients,
families linked to the ALS5 locus do not present with spasticity
of limb, facial, and tongue muscles [7]. Genetic analysis of
different kindreds with this type of rare and recessive ALS did
not show linkage to markers on chromosome 2q33, suggesting
genetic locus heterogeneity and making ALS5 a distinct genetic
entity. A genome-wide search in different families from North
Africa, Tunisia and Germany with the disorder established
linkage on chromosome 15q15.1–q21.1 between D15S146 and
D15S123 [7].
2.6. ALS6 (OMIM: 606030)
Three independent studies have reported linkage of unlinked
dominant adult-onset typical ALS families to chromosome 6
[61–63]. One group has performed a genome-wide screen in
sixteen pedigrees from the United States with familial ALS in
which no mutations in the SOD1 gene were found. They
identified a novel ALS locus, designated ALS6, in one family,
with a candidate region spanning 51-cM (38-Mb) on chromo-
some 16p12.1–16q21 [63]. A second group performed a
genome screen of ALS families from the United Kingdom
lacking SOD1 mutations [61]. They identified the same ALS6
locus on chromosome 16q12.1–q12.2 and refined the candidate
region to a 14.74-cM genetic interval, which corresponds to a
physical distance of 6.6 Mb. Finally, a third group also reported
linkage to the same region by performing a genome-wide
linkage screen in two large European families with ALS without
SOD1 mutations [62]. Their results led to further refinement of
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reported ALS6-linked families, seemingly from different
origins, do not share the same disease haplotype, suggesting
that more than one gene within the candidate region or different
mutations in the same gene could underlie ALS6.
2.7. ALS7 (OMIM: 608631)
A FALS locus on chromosome 20, named ALS7, has also
been identified in the same genetic analysis performed in the
sixteen U.S. non-SOD1 pedigrees with dominant familial ALS
mentioned above [63]. They established linkage in one family
and the candidate region spans 6.25 cM (1 Mb) on
chromosome 20ptel-p13 with a two-point lod score over 3.0.
Two contiguous markers (D20S103 and D20S117) led to a
multipoint LOD score maximum value of 3.46 at D20S103.
The genetic evidence that ALS7 stands on a distinct genetic
entity is not very strong, as similar linkage in other families
has not been replicated and this locus has been identified
based on genotypes of only two affected individuals, both in
the same generation. Identifying other ALS families linked to
ALS7 or collecting additional family members of the
described pedigree will help to confirm this locus.
2.8. ALS8 (OMIM: 608627)
A genome-wide genetic screen of a large Caucasian Brazilian
family with autosomal dominant late-onset atypical ALS yielded
evidence for linkage to chromosome 20q13.33 with a maximum
lod score 6.02 [64]. The reported 2.7-Mb region is flanked by
markers D20S430 and D20S173. Further investigation led to the
identification of a missense P56S mutation in the VAPB gene
segregating within the same described Brazilian family [65].
This large family with twenty-six affected members distributed
in three generations showed clinical and neurological signs that
may be compatible with ALS. The phenotype is characterized by
slow progression of the disease, a clinical onset occurring
between 31 and 45 years, lower motor neuron symptoms in all
patients, postural tremor, cramps and fasciculations. The
presence of atypical signs, such as essential tremor and lower
motor neuron degeneration with no upper motor neuron
involvement, which is rarely seen in typical ALS, may also be
compatible with spinal muscular atrophy.
The vesicle-associated membrane protein B gene (VAPB)
comprises six exons spanning over 57.7 kb of genomic DNA. It
encodes a 33-kDa protein, named VAMP-B or VAP-33,
containing two hundred and forty-three residues. The protein
encoded by this gene is a membrane protein found in plasma and
intracellular vesicle membranes, and can associate with micro-
tubules [66]. VAMP-B protein is found as a homodimer, or as a
heterodimer with VAMP-A, another vesicle-associated mem-
brane protein. VAMP-B can also interact with synaptobrevin-1
(VAMP-1) and synaptobrevin-2 (VAMP-2), and may be
involved in vesicle trafficking [66,67]. The VAMP-B protein
contains three distinct structural domains including an amino-
acid terminal MSP domain (Major Sperm Protein), a central
region containing an amphipathic helical structure predicted toform a coiled/coil protein–protein interaction motif and a
hydrophobic carboxy terminus trans-membrane domain [67,68].
2.8.1. VAPB mutation
The P56S missense mutation initially described in a
Brazilian family was also found in seven additional kindreds
with variable clinical manifestations including late-onset spinal
muscular atrophy and late-onset atypical ALS with slow
progression [65]. Intra- and inter-familial heterogeneity sug-
gests the presence of modifying or environmental factors that
could alter the clinical phenotype. The proline to serine change
at codon 56 was generated by a C to T substitution at nucleotide
166 within exon 2 of the VAPB gene. This proline is highly
conserved among several species and was not detected in
unaffected siblings and in four hundred control chromosomes of
normal individuals. To date, there are eight families including
over two hundred affected individuals bearing the P56S
mutation. Seven of these families are from Portuguese origin
and one is from African origin. Haplotype analysis showed a
common founder for all families regardless of origin [69]. It is
unlikely that phenotypic variability between patients can be
explain by a cis-acting element close to the VAPB gene, as the
genetic background around the VAPB gene is common to all
affected individuals with the P56S mutation [69]. One patient in
one kindred also developed typical ALS, while other affected
members had symptoms that are more related to late-onset
spinal muscular atrophy. It is possible that this ALS patient
could in fact be suffering from sporadic ALS. The ALS
symptoms seen in this patient may mask another co-segregating
neurological disorder leading to an alternative ALS diagnosis.
Indeed, a characteristic muscular atrophy phenotype, called
spinal muscular atrophy type Finkel (OMIM: 182980), was
described in 1962 in a Portuguese-Brazilian family and an
African-Brazilian family [70]. However, it is not excluded that
the noticed genetic heterogeneity could be explained by
modifier or environmental factors. It would be interesting to
see if mutations in the VAPB gene can be associated with typical
dominant ALS in other families from different origins.
2.8.2. VAPB animal models
There are nomousemodels forVAPB, even though the protein is
highly conserved in the mouse. However, in drosophila, male
mutants die in early larva stage and show severemotor deficits and a
severely compromised synaptic microtubule assembly [71].
2.9. ALS with frontotemporal dementia (OMIM: 105550)
Coexistence of frontotemporal dementia (FTD) and ALS
was first described in 1975 [72]. To study the genetics
underlying this condition, a genome-wide screen was performed
using two distinct data sets comprising over seven hundred non-
SOD1 families with ALS (each with at least two individuals
diagnosed as having ALS) [73]. A genetic locus was identified
between markers D9S301 and D9S167 on 17-cM region on
chromosome 9q21–q22, using families in which individuals
develop both ALS and FTD or either ALS or FTD alone. The
wide range of clinical features among families suggests that
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phenotype. Families with ALS alone did not link to this
locus. It is likely that this new locus represents a distinct genetic
entity from the previously reported ALS locus on chromosome
9q34 as the two regions do no overlap with each other, the
pattern of inheritance as well as age of onset is different, and the
phenotype associated with each locus is clinically distinct. As
similar conjoined ALS-FTD phenotype has also been described
in a Swedish family without linkage to chromosome 9q21–q22,
suggesting genetic heterogeneity for this particular subclass of
neurodegenerative disease [74].
2.10. ALS with frontotemporal dementia and Parkinson
,
s
disease (FTDP) (OMIM: 600274)
Motor neuron degeneration can also occasionally occur in
patients with Parkinson's disease and frontotemporal dementia.
This disease is also called Disinhibition–dementia–parkinson-
ism–amyotrophy complex (DDPAC) or FTDP17 [75]. The
pathologic features distinguish this disease from the ALS–
parkinsonism–dementia complex of Guam seen in the penin-
sula of Japan and from ALS–FTD linked to chromosome 9.
Mutations in the microtubule-associated protein tau gene
(MAPT) are associated with FTD and Parkinsonism [76,77].
The human MAPT gene is located on chromosome 17q21 and
consists of a fourteen coding or partially coding exons [78].
This gene can undergo multiple splicing events and this has led
to confusion about the number of MAPT exons. Interestingly,
intron 13 is always retained in human MAPT mRNAs, although
it is removed in some mouse transcripts by RNA splicing [79].
Rademakers and colleagues favored the definition of fifteen
exons: with exon 13, intron 13, and exon 14 being a single exon.
The last exon comprises the 3′-untranslated region.
Tau is a member of the microtubule-associated protein
family, which have the principal function stabilizing micro-
tubules and promoting their assembly by binding to tubulin
[80]. In addition, tau is likely to regulate motor protein-
mediated transport of vesicles and organelles along the
microtubules by modulating their stability [81,82].
2.10.1. MAPT mutations
Various mutations have been identified in the MAPT gene
including intronic, splice site and missense mutations [76,77,
83]. Considerable variability in clinical and pathologic presen-
tation of patients with MAPT mutations can be seen. However,
not all patients showing ALS symptoms with FTD and
Parkinson's disease have MAPT mutations, suggesting again
here, as well as with other FALS loci and ALS–FTD, genetic
heterogeneity.
2.10.2. MAPT animal model
Different transgenic mice models overexpressing different
human tau isoforms either ubiquitously or specifically in
neurons have been generated [84–87]. These mice acquire
age-dependent central nervous system pathology similar to
FTDP17 including axonal degeneration in brain and spinal cord,
progressive motor disturbance and behavioral impairment.2.11. Progressive LMN disease, dynactin type (OMIM: 607641)
Another linkage to chromosome 2 has been identified in a
family with a slowly progressive and rare autosomal dominant
form of motor neuron disease without sensory symptoms [88].
Age of onset is in early adulthood and patients develop
breathing difficulties due to vocal fold paralysis, progressive
facial weakness and muscle atrophy in the hands. Weakness and
muscle atrophy in the distal lower extremities were also noted in
affected individuals. Some, but not all, clinical features overlap
with ALS. A genome-wide screen established linkage to
chromosome 2p13 between markers D2S291 and D2S2114,
with a maximum lod score of 4.05 [88]. Mutation analysis of a
gene called dynactin1 (DCTN1), encoding the largest subunit of
the axonal transport protein, showed a missense mutation
resulting in an amino acid substitution that is predicted to distort
the folding of dynactin's microtubule-binding domain. Dynac-
tin is a heteromultimeric protein complex consisting of at least
seven different polypeptides that binds to both microtubules and
cytoplasmic dynein during vesicle transport [89].
2.11.1. DCTN1 mutations
The DCTN1 gene encodes the largest subunit of dynactin, a
macromolecular complex consisting of ten to eleven subunits
ranging in size from 22 to 150 kDa. It spans approximately
19.7-kb of genomic DNA and consists of at least thirty-two
exons. A single-basepair change in the DCTN1 gene, resulting
in an amino acid substitution of serine for glycine at position 59,
was first identified in all affected individuals presenting with
progressive LMN disease [88]. The G59S substitution occurred
in the highly conserved CAP-Gly motif of the p150 subunit of
dynactin, a domain that binds directly to microtubules. Three
heterozygous missense mutations of the DCTN1 gene were also
detected in two other families [90]. The authors distinguished
the phenotype in their patients from the G59S-linked previously
reported ones by the presence of upper motor neuron signs and
suggested that mutations in the DCTN1 gene may be a
susceptibility factor for ALS.
2.11.2. DCTN1 animal models
Transgenic mice overexpressing the p150 subunit of
dynactin in which disruption of the complex occurs have been
found to develop a late onset, progressive motor neuron disease
[91]. Dominant negative mutations in the Drosophila melano-
gaster homolog for DCTN1 produce an abnormal eye formation
in heterozygous flies with severe disruption in the organization
of the retina and in the retinal axonal projections [92]. An
RNAi-based screen in flies targeted against different subunit of
the dynactin complex including the p150 subunit showed that
dynactin functions locally within the presynaptic arbor to
promote synapse stability at the neuromuscular junction [93].
3. Sporadic ALS
The etiology and pathogenesis of amyotrophic lateral
sclerosis remain largely unknown. A genetic component is
also thought to contribute to the pathogenesis of sporadic ALS,
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identification of gene defects in SALS cases has met with limited
success so far. Several groups have reported on gene variants and
association studies found in individuals with sporadic ALS.
These studies linked SALS to particular genetic variants account
for a small number of the total cases reflecting a complex pattern
of inheritance with very low penetrance, a high degree of
heterogeneity and/or the existence of environmental factors
predisposing to ALS. With the exception of few familial ALS
cases in which other neurodegenerative disorders can simulta-
neously occur, FALS and SALS are clinically indistinguishable.
However, there are some minor interesting differences. The
mean age of onset in familial cases (∼46 years), is earlier than
those with sporadic ALS (∼56 years) [13]. A 1:1 male to female
ratio is observed in FALS while in SALS an unexplained male
preponderance of 1.5:1 is reported worldwide, although this
ratio tends to decrease and approaches 1:1 after age 70 [94].
3.1. Superoxide dismutase 1 (SOD1)
SOD1 mutations have been shown to be associated with 10–
15% of FALS. Some reports have also identified SOD1 mutations
in apparent SALS patients. The incidence of SOD1 mutations in
SALS patients varies in different surveys and it ranges from1 to 7%
[95–99]. All described SOD1-linked SALS mutations do not have
specific phenotypic characteristics that distinguish them from
other non-linked SALS patients. The mean age at onset in
mutant SOD1-linked SALS patients is 41.4 years, which is about
10 years below the mean age at onset described in patients with
sporadic ALS without SOD1 mutations [95]. However, further
studies are needed to support this finding. The most frequent
SOD1mutation detected in SALS cases worldwide is the I113T
mutation. It is unclear whether or not the SOD1-linked SALS
patients are truly sporadic, as incomplete disease penetrance has
been associated with different described SOD1 mutations
including the I113T [100]. Moreover, some of the reported
mutations in SALS have also been associated with FALS which
makes it difficult to distinguish sporadic cases from familial
ones at the genetic level [101].
3.2. Dynactin (DCTN1)
As mentioned earlier, mutations in the p150 subunit of the
DCTN1 gene lead to progressive lower motor neuron disease
with atypical ALS features in some unrelated families [88,90].
AT1249I mutation in exon 13 of this gene has also been found
to be associated with sporadic ALS [90]. However, such as in
sporadic SOD1-linked SALS, an incomplete penetrance of this
mutation in conjunction with other predisposing genetic factors
has to be taken into consideration. So, the apparently sporadic
patient bearing a mutation in this gene might have been
misdiagnosed and could in fact be a familial case.
3.3. Neurofilaments
Abnormal accumulation of neurofilaments is a pathological
feature of several neurodegenerative diseases, including ALS,Alzheimer's disease, Parkinson's disease, dementia with Lewy
bodies, and diabetic neuropathy. Neurofilaments, the major type
of intermediate neurofilaments expressed in adult neurons, are
formed by the coassembly of three type IV intermediate neu-
rofilament proteins, the neurofilament light (NF-L), neurofila-
ment medium (NF-M) and neurofilament heavy (NF-H) sub-
units. There is also growing evidence for potential peripherin
involvement, a type III intermediate neurofilament, in human
disease.
Currently, it remains unclear to what extent intermediate
neurofilamant abnormalities contribute to ALS pathogenesis. It
has been postulated that defects in axonal transport may be an
underlying common pathway that leads to the degeneration of
motor neurons in ALS patients and transgenic SOD1 mouse
models. Uniquely characterized by their length, motor neurons
of the brain and spinal cord can reach a meter in length in an
adult human. The significant length of these axons makes active
axonal transport, both anterograde and retrograde, essential for
normal cellular function.
3.3.1. Mutations in neurofilamant subunits (NEFH, NEFM and
NEFL)
Codon deletions or insertions in the KSP phosphorylation
domain of NEFH have been detected in a small number of
sporadic cases of ALS (approximately 1% of total cases) [102–
104]. However, even if the functional consequences of these
NEFH phosphorylation variants are unknown, these variants are
viewed as risk factors for the disease. Missense mutations and a
3-bp in-frame deletion in the NEFL gene subunit have also been
also reported in patients with Charcot–Marie–Tooth type 2
neurodegeneration [105,106]. Genetic variations within NEFM
have also been associated with Parkinson's disease.
3.3.2. Peripherin (PRPH)
Peripherin is a type III intermediate neurofilamant protein
expressed predominantly in the peripheral nervous system, with
low levels detectable in spinal motor neurons [107,108]. Up-
regulation of peripherin mRNA has recently been observed in a
familial ALS case [109]. Under certain conditions, including in
transgenic mice expressing a mutant form of SOD1 linked to
ALS, the murine Prph gene was found to produce different par-
ticular Prph splicing species, which are assembly-incompetent
and toxic when expressed in cultured neuronal cells [109]. The
recent identification of a frameshift mutation in the peripherin
gene of a patient with SALS strongly argues in favor of neuro-
filament involvement in ALS [110]. Of particular interest is that
the detected PRPH frameshift deletion mutant expression leads
to the disruption of neurofilament assembly in cultured cells.
3.3.3. Neurofilament animal models
Several transgenic mouse lines and knockout mice impli-
cating different neurofilament subunits have been extensively
studied over the past years (for review see, [111]). The study of
the phenotype in the neurofilament overexpressor mouse mod-
els led to some interesting findings, including neurodegenera-
tion, abnormal accumulation of intermediate neurofilament,
which is reminiscent of what was found in ALS patients and
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detected in NEFL null mice and double NEFM/NEFH knockout
[97,112]. Overexpression of peripherin in NEFL null back-
ground mice induces motor neuron disease [113], and provoke
death when expressed in cultured motor neurons [114]. The
precise mechanism by which accumulation of intermediate
neurofilament leads to neurodegenerative disorders is not fully
understood. It has been proposed that the severe loss of motor
neurons seen in these transgenic mouse models might be caused
by the disruption of axonal transport.
3.4. Vascular endothelial cell growth factor (VEGF)
VEGF, first discovered as a tumor-secreted protein that
promotes the formation of new blood vessels and vascular
permeability, is an important angiogenesis factor [115]. The first
implication of VEGF in ALS came with the description of a
mouse model where deletion of the hypoxia-response element
in the Vegf promoter leads to muscle weakness, atrophy, and
death due to degeneration of lower motor neurons [116]. The
precise mechanism through which reduced VEGF levels result
in an ALS-like phenotype in these mice is not clear: both
chronic neuronal ischemia and loss of a direct trophic effect of
VEGF on motor neurons have been proposed [116,117].
Interestingly, intercross of the VEGF mutant mice with
transgenic mice overexpressing mutant G93A-SOD1 led to a
more severe phenotype with earlier age of onset [118]. This
finding may indicate that VEGF is a modifier of motoneuron
degeneration in SOD1-linked ALS mouse. In a meta-analysis of
over one thousand and nine hundred individuals, three polymor-
phisms in the VEGF promoter/leader sequence have been
associated with an overall 1.8-fold increase risk of developing
ALS [118]. Further investigations of VEGF promoter elements
have confirmed these results in one other population [119] but
failed to be reproduced it in others [120,121].
3.5. Survival motor neuron (SMN)
The search for a link between spinal muscular atrophy (SMA)
and ALS has been extensively pursued in many epidemiological
studies. SMA is caused by homozygous mutations in the
survival motor neuron 1 gene (SMN1) [122]. The SMN1 gene
maps to chromosome 5q13.3 in a 0.5-Mb duplicated region. So,
two copies of SMN exist, the telomeric copy called SMN1 and
the centromeric copy called SMN2. These highly homologous
genes contain nine exons and encode an identical two hundred
and ninety-four amino acid long protein. A one nucleotide
difference within the full-length cDNA sequence of exon 7 leads
to alternative splicing events, and distinguishes SMN1 from
SMN2 [123,124]. SMN2 gene deletions are not associated with
SMA but may represent possible risk factors for lower motor
neuron disease [125]. Several conflicting studies have been
conducted to investigate whether alterations of SMN1 or SMN2
are possible genetic risk factors for ALS. An overrepresentation
of SMN2 gene deletions were found in 16% of patients with
sporadic ALS, compared to only 4% in normal non-affected
individuals [126]. In contrast, another study reported nodifferences in SMN2 copy number and surprisingly showed an
abnormal SMN1 copy number in sporadic ALS patients [127]. A
recent study showed a decrease in the copy numbers of both
SMN1 and SMN2 associated with increase susceptibility to
develop ALS [128]. These conflicting data may result from the
use of moderate size populations and the use of inappropriate
control populations (in which ethnic origin, age and gender
matching would be critical to find significant statistical
associations). Interestingly, genetic mapping of a modifying
locus that could delay disease progression in SOD1mutant mice
showed strong genetic evidence for a locus on chromosome 13
comprising the Smn gene and the neuronal apoptosis inhibitory
protein (Naip) gene [32]. Three different groups found, however,
that NAIP gene mutations are specific for spinal muscular
atrophy and do not predispose to sporadic ALS [129–131]. The
SMA critical region contains several genes with duplications
that could be important for motor neuron metabolism. Positional
cloning and sequencing of this region could, therefore, reveal
additional polymorphisms relevant to ALS.
3.5.1. SMN animal models
The establishment of a mouse model for human SMA in
which the Smn1 gene has been knocked-out leads to
developmental arrest and death during peri-implantation stage
[132]. However, transgenic mice expressing the human SMN2
gene in the Smn−/− background showed pathological character-
istics and variable phenotypic changes mimicking those found
in human SMA [132]. In addition, a strong correlation between
SMN2 copy number and severity of the phenotype were noted
[133]. The SMA-like mice also exhibited a massive accumu-
lation of neurofilaments, which is reminiscent of mouse and
human SOD1-linked FALS [134].
3.6. Glutamate excitotoxicity
Glutamate is the major excitatory neurotransmitter in the
brain and is suspected to play a role in the etiology of ALS.
Glutamate is released from presynaptic terminals, is Ca2+-
dependant and activates specific receptors (AMPA and/or
GluRs) on postsynaptic neurons by diffusing across the synaptic
cleft. Repetitive motor neuron firing can lead to excitotoxic
death if glutamate release is not cleared properly at the
postsynaptic dendrites of upper and lower motor neurons.
Glutamate transporters are key components of the mechanism
necessary to clear glutamate from the synaptic cleft and prevent
neurotoxic effects and neuronal death. There is evidence for
glutamate excitotoxicity involvement in ALS, namely changes
in glutamate levels in the cerebrospinal fluid of ALS patients
[135,136]. Furthermore, the level of EAAT2 (also called GLT-1),
the main astroglial glutamate transporter, is found to be severely
reduced both in the motor cortex and in the spinal cord from
sporadic ALS patients [137]. Abnormal EAAT2 mRNA was
subsequently detected in sporadic ALS patients, offering an
explanation for the reduction in EAAT2 protein levels [138].
Aberrant EAAT2 mRNA splicing is seen in about 65% of
sporadic ALS patients, and this defect might exert a dominant
negative effect resulting in the glutamate-mediated motor
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aberrant mRNA transcripts of EAAT2 in ALS cases could not be
explained by mutations in the EAAT2 gene [139–141]. An
abnormal editing of the messenger RNA encoding the GluR2
subunit of glutamate AMPA receptors in the spinal motor
neurons of individuals affected by ALS has also been reported
and this defect may be a contributing factor to neuronal death in
ALS patients [142]. Interestingly, treatment of ALS patients with
riluzole, the only drug approved for ALS, blocks glutamate
release from presynaptic neurons and has been shown to prolong
survival in patients [143].
3.7. Ciliary neurotrophic factor (CNTF)
The protein encoded by the CNTF gene is a polypeptide
hormone whose actions appear to be restricted to the nervous
system, where it promotes neurotransmitter synthesis and neurite
outgrowth in certain neuronal populations, and may also be
required for survival of motor neurons in vivo [144]. A mutation
in this gene, which results in aberrant splicing, leads to ciliary
neurotrophic factor deficiency but it is not causally related to
neurological disease [145]. A study in a SOD1-linked family,
bearing the SOD1 V148G mutation and showing intra-familial
phenotypic variability, revealed a homozygous null mutation in
the CNTF gene in one affected individual [146]. This 25-year-
old patient bearing both mutations died of ALS eleven months
after onset of the disease, while other affected members of the
family bearing either the V148G mutation alone or with hete-
rozygous CNTF mutations developed ALS between ages of
43 and 62 years. Crossbreeding between the described
G93A-SOD1 transgenic mice and CNTF null mice leads to
a characteristic ALS phenotype with earlier age of onset for
G93A-SOD1/CNTF−/− mice, when compare to G93A-SOD1
transgenic mice alone [146]. No changes in the disease prog-
ression were noted in these double mutant mice and no differ-
ences in age of onset nor in disease progression were noticed
between G93A-SOD1 mice and G93A-SOD1/CNTF+/− mice.
These observations suggest that CNTF may be a modifying
factor of SOD1-linked ALS. Of particular interest, about 2% of
the general population may carry homozygousCNTFmutations,
but several studies showed that these variants are not risk factors
for neurological disease, including ALS [145,147–150]. A
study using four hundred ALS patients did not find any differ-
ences in age of onset, clinical presentation, rate of progression,
or disease duration for ALS patients bearing one or two copies of
the null allele, excluding CNTF as a major disease modifier in
ALS [147]. However, further studies are needed to assess the
impact of CNTF as a candidate modifier gene for ALS.
3.8. Other candidate genes
Several studies showed either positive or negative association
with potential candidate genes in different cohorts of sporadic
ALS patients. The use of an inappropriate sample size or
inappropriate controls regarding ethnicity, age and gender may
explain the lack of reproducibility in all these seemingly
statistically underpowered studies.3.8.1. Apolipoprotein E (APOE)
Investigation of the effect of Apolipoprotein E (APOE), a
confirmed risk factor for different neurodegenerative disorders
including Alzheimer's disease, Parkinson's disease and multi-
ple sclerosis, led to conflicting data regarding the implication of
the APOEε4 genotype on the risk of developing ALS [151–
156]. Conflicting data regarding the association of SALS with
this particular APOEε4 genotype and phenotypic variations
regarding age at onset, site of onset, and duration of the disease
have also been reported in many studies [151–156].
3.8.2. DNA repair enzyme apurinic/apyrimidinic endonuclease
(APEX)
Defects in DNA repair enzymes have been proposed as
underlying mechanisms predisposing to ALS. It was reported
that levels of the DNA repair enzyme apurinic/apyrimidinic
endonuclease called APEX were reduced in the frontal cortex of
patients with sporadic ALS [157]. APEX gene mutations were
reported by different groups, but they do not seem to account for
a large proportion of ALS cases [158–161].
3.8.3. Angiogenin (ANG)
ANG is located 237-kb downstream of APEX and is a potent
mediator of new blood vessel formation, similar to VEGFwhich
has been found to increase the risk of developing ALS [118].
Starting from the hypothesis that VEGF pathway might be also
involved in ALS and keeping in mind that the described
association with polymorphisms within the APEX gene might
not be linked to APEX itself but to a gene in close proximity, a
group has identified another more robust allelic association with
the ANG gene [158].
3.8.3.1. Hemochromatosis gene (HFE). Increased oxidative
stress is likely to play a role in mediating the different patho-
genic mechanisms leading to motor neuron death in SOD1-
linked and unlinked ALS. Several studies have found evidence
of elevated iron levels in ALS-affected tissue. The misregula-
tion of iron, a detrimental catalyst in biological free radical
oxidations, can amplify the formation of reactive oxygen
species by driving the Fenton reaction or through other non-
Fenton mechanisms [162]. Therefore, processes that result in
iron accumulation may confer susceptibility to neurodegener-
ative diseases such as ALS. Mutations in the HFE gene are
associated with an iron overload disease known as hemochro-
matosis [163], and rare polymorphisms in this gene have also
been reported to be associated with sporadic ALS [164–166].
Further studies are needed to confirm this association and to
determine the relationship between variations within this gene
and ALS.
3.9. Other chromosome rearrangements
In the general population, the prevalence of balanced
chromosomal abnormalities is low, but an increased rate of
constitutional chromosomal rearrangements in apparently
sporadic ALS was reported in various studies [167,168].
Four constitutional translocations in sporadic ALS patients
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q11.2), and t(18;21)(q23;q22). Two pericentric inversions, inv
(X)(p11.2q21.3) and inv(12)(p11q13) have also been identi-
fied. One of these translocations involves chromosomes 18
and 21, two chromosomes where FALS loci have been
previously described. The chromosomal breakpoints on
chromosome 21 localize to the 21q22 region, which harbors
the ALS-associated SOD1 gene, but a physical involvement
of the SOD1 gene has been excluded. This suggests the
presence of another genetic susceptibility locus [169].
Considering the relatively small size of the different studied
populations, further studies conducted in larger ALS popula-
tions are needed to confirm these results. It would be of great
interest to know if those chromosomal rearrangements disrupt
or define sets of functionally significant genes and how such
genetic rearrangements could lead to ALS.
4. Environmental factors
There is some evidence of gene-to-gene interaction or gene
and/or environmental factors in ALS. For instance, Parkinson-
ism with progressive dementia complex (PDC) is recognized as
a clinical variant of a form of ALS that occurs to a high
incidence among the Chamorro people of the island of Guam.
The illness has dramatically declined in the last two decades,
but incident cases of ALS, Parkinsonism and dementia alone or
together, with mixed manifestations, are still being diagnosed
albeit at much lower incidence. The epidemiological evidence
for a major environmental determinant in the causation of ALS/
PDC is very strong, although the possibility of the existence of
significant genetic determinants of disease phenotypes within
families has also been suggested and is under active inves-
tigation. The high prevalence of a specific polymorphism in the
MAPT gene in the ALS Guam population implicates this gene
as a potential modifying factor [170]. The major environmental
hypotheses associated with the disease on the island of Guam
are toxicity owing to ingestion of cycad-based foods, an
unknown slow viral agent, or an imbalance in water mineral
content causing a parathyroid disorder that affects calcium,
magnesium and aluminium metabolism [171,172]. Interesting-
ly, a specific gene-to-environment interaction between MAPT
and cycad toxin has been reported to modulate the MAPT
mRNA expression [173]. The theory that a related toxin called
β-methylaminoalanine (BMAA), a potent excitotoxin of gluta-
mate receptors found in the cycad fruit, was frequently brought
into question due to a relatively low level detection of BMAA in
the diet of the Chamorro people of Guam [174]. The cycad
hypothesis has recently been revised by a report witch showed
that biomagnification leads to an increased accumulation of
bioactive neurotoxic BMAA in the Guam ecosystem [175,176].
It has been shown that BMAA can be biomagnified in flying
foxes, which were often present in the diet of the Guam people.
The biomagnification of BMAA through the Guam ecosystem
may explain the higher incidence of ALS-PDC seen among the
Chamorro people of Guam. Further investigations are needed to
confirm these results and it would be interesting to investigate if
flying foxes develop ALS.Other environmental risk factors, including behavioral and
occupational exposures, have been investigated in ALS patients,
but no significant specific factor has been consistently related to
ALS. Smoking has been proposed as a risk factor in ALS
[177,178] but it remains in question [179]. The association of
physical activity and ALS has stimulated great interest over the
past years, but no consistent links with exercise or trauma have
been observed to increase the risk of developing ALS [180,181].
Exposure to pesticides or solvents has also been studied in ALS.
Chemicals used in agricultural work could play a possible role of
developing ALS [182,183] but, this finding lacks replication by
other groups.
5. Discussion
Despite extensive research progress in ALS and other motor
neuron diseases over the past decade, the mechanism of
pathogenesis in ALS is still largely unknown and no effective
therapy is yet available. Genetic analysis has identified a primary
cause of FALS occurring in about 2% of the total cases. The
number of different loci and reported mutations that have been
identified in families with FALS make this form of the disease
highly heterogeneous. Some mutations in several genes have
also been associated with sporadic ALS, accounting for a small
percentage of the total cases. An important issue in the study of
Mendelian diseases is the phenomenon of genetic heterogeneity,
whereby distinct mutations at the same locus or different loci can
cause the same, indistinguishable phenotype. A more complex
scenario has to be taken into consideration where many different
genes, each with allelic variations, contribute to the total
variability observed in the trait, with no particular gene having a
single large effect. The identification of other genetic variations
will have direct implications in ALS research in particular, and
motor neuron diseases in general.
It thus appears that inherited ALS will show a high degree of
genetic heterogeneity, as well as clinical diversity. This has
implications for genetic linkage analysis strategies, rendering the
conventional approach of establishing linkage with multiple
large families exceedingly difficult. However, linkage analysis,
association and case control studies have allowed the identifi-
cation of a number of genetic factors leading or predisposing to
ALS. It remains to be determined whether the various ALS-
related genes identified so far define sets of functionally
significant, interacting genes. If this is the case, an understanding
of the functions of the associated proteins and pathways may
provide further insight into the pathogenesis of this disease and
ultimately lead to new approaches to treatment.
Many conflicting data generated by different groups who
have studied different populations around the world have been
published. The use of an adequate size population with
appropriate control individuals is needed in order to reach
enough statistical power and to observe significant results.
Homogeneity regarding ethnical origin, age, age of onset,
disease duration, site of the first symptoms and gender among a
particular population is essential to design a good and robust
genetic study. The requirement for larger sample sizes and
possibly more sensitive and efficient analytic tools that allow for
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future as non cost-effective genotyping strategies become more
and more available.
6. Conclusions
It has been over 13 years since the first mutation description
in the SOD1 gene in ALS patients. Identification of other major
genes that could explain the majority of ALS cases is still a
challenge. High genetic heterogeneity and complex interactions
between genetic and environmental factors are the main
obstacles in the process of finding new ALS genetic determi-
nants. Therefore, ALS should be referred to as a multifactorial
complex disease.
A common pathway among all identified genes and genetic
factors associated with ALS is becoming apparent and involves
intracellular cell trafficking and axonal transport. To what extent
these related pathways are implicated in ALS remain to be
determined. It is interesting to note that genes such as ALS2,
VAPB, MAPT, DCTN1, EAAT2, NEFH, PRPH and CNTF, in
which mutations have been found in a subset of ALS patients,
are all related to intracellular trafficking either via axonal
transport, vesicle docking and transport, or microtubule and
neurofilament stabilization. Furthermore, this common theme is
also seen in other motor neuron diseases and neurodegenerative
disorders such as hereditary spastic paraplegia, Parkinson's
disease, spinal muscular atrophy and Charcot–Marie–Tooth
disease. It is also noteworthy that alternative splicing abnor-
malities are also involved in different ALS related genes such as
ALS2,MAPT, EAAT2, PRPH, GluR2, CNTF, SMN1 and SMN2.
Such genetic defects, in combination with other genetic
rearrangements and heterogeneity, suggest that an individual
phenotype could result from the sum of several contributing
gene defects and epigenetic influences which individually do
not cause disease, and could explain the difficulties in
identifying genes that cause ALS. The identification of other
genes associated with motor neuron disease, as well as the
determination of genetic and/or environmental factors that
predispose to sporadic ALS are critical in the development of
therapies for ALS. The generation of other ALS animal models
in which the disease can be closely replicated would also be the
utmost importance to reach a full understanding of the
molecular mechanisms and environmental factors that cause
ALS.
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